Loading...

Dr. Jeffrey Zonder: Pomalidomide/bortezomib/dex in amyloidosis, light chain dep. disease (ASH 2014)

708 views

Loading...

Loading...

Transcript

The interactive transcript could not be loaded.

Loading...

Rating is available when the video has been rented.
This feature is not available right now. Please try again later.
Published on Dec 19, 2014

Dr. Jeffrey Zonder (Karmanos Cancer Institute, Wayne State University, Detroit, Michigan) discusses results from a phase I clinical trial of pomalidomide (Pomalyst/ Imnovid), bortezomib (Velcade), and dexamethasone as initial treatment of AL amyloidosis and light chain deposition disease. These phase I study results were presented at the 56th American Society of Hematology (ASH) Annual Meeting. ASH 2014 abstract 4746.

Please subscribe to our channel!
Subscribe to International Myeloma Foundation: http://bit.ly/XlUtPE

Visit our website at: http://www.myeloma.org

Find us online:
Facebook: http://facebook.com/myeloma
Google+: http://gplus.to/imfmyeloma
IMF on twitter: @IMFMyeloma (http://twitter.com/imfmyeloma)
Dr. Durie on twitter: @BrianDurieMD (http://twitter.com/brianduriemd)

Support the IMF! http://bit.ly/WskQHC
Category
Nonprofits & Activism
License
Standard YouTube License

Loading...

When autoplay is enabled, a suggested video will automatically play next.

Up next


to add this to Watch Later

Add to

Loading playlists...